These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 32116096)

  • 21. A simple, versatile and robust centrifugation-based filtration protocol for the isolation and quantification of α-synuclein monomers, oligomers and fibrils: Towards improving experimental reproducibility in α-synuclein research.
    Kumar ST; Donzelli S; Chiki A; Syed MMK; Lashuel HA
    J Neurochem; 2020 Apr; 153(1):103-119. PubMed ID: 31925956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models.
    Sato H; Kato T; Arawaka S
    Rev Neurosci; 2013; 24(2):115-23. PubMed ID: 23314528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mitochondrial Dysfunction, Protein Misfolding and Neuroinflammation in Parkinson's Disease: Roads to Biomarker Discovery.
    Picca A; Guerra F; Calvani R; Romano R; Coelho-Júnior HJ; Bucci C; Marzetti E
    Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Binding of Noradrenaline to Native and Intermediate States during the Fibrillation of α-Synuclein Leads to the Formation of Stable and Structured Cytotoxic Species.
    Singh P; Bhat R
    ACS Chem Neurosci; 2019 Jun; 10(6):2741-2755. PubMed ID: 30917654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration.
    Mahul-Mellier AL; Burtscher J; Maharjan N; Weerens L; Croisier M; Kuttler F; Leleu M; Knott GW; Lashuel HA
    Proc Natl Acad Sci U S A; 2020 Mar; 117(9):4971-4982. PubMed ID: 32075919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease.
    Benskey MJ; Perez RG; Manfredsson FP
    J Neurochem; 2016 May; 137(3):331-59. PubMed ID: 26852372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Graphene quantum dots prevent α-synucleinopathy in Parkinson's disease.
    Kim D; Yoo JM; Hwang H; Lee J; Lee SH; Yun SP; Park MJ; Lee M; Choi S; Kwon SH; Lee S; Kwon SH; Kim S; Park YJ; Kinoshita M; Lee YH; Shin S; Paik SR; Lee SJ; Lee S; Hong BH; Ko HS
    Nat Nanotechnol; 2018 Sep; 13(9):812-818. PubMed ID: 29988049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreased AQP4 Expression Aggravates ɑ-Synuclein Pathology in Parkinson's Disease Mice, Possibly via Impaired Glymphatic Clearance.
    Cui H; Wang W; Zheng X; Xia D; Liu H; Qin C; Tian H; Teng J
    J Mol Neurosci; 2021 Dec; 71(12):2500-2513. PubMed ID: 33772424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-invasive systemic viral delivery of human alpha-synuclein mimics selective and progressive neuropathology of Parkinson's disease in rodent brains.
    Bérard M; Martínez-Drudis L; Sheta R; El-Agnaf OMA; Oueslati A
    Mol Neurodegener; 2023 Nov; 18(1):91. PubMed ID: 38012703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. α-Synuclein and Lewy pathology in Parkinson's disease.
    Kalia LV; Kalia SK
    Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The interaction between alpha-synuclein and mitochondrial dysfunction in Parkinson's disease.
    Li HY; Liu DS; Zhang YB; Rong H; Zhang XJ
    Biophys Chem; 2023 Dec; 303():107122. PubMed ID: 37839353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production.
    Tapias V; Hu X; Luk KC; Sanders LH; Lee VM; Greenamyre JT
    Cell Mol Life Sci; 2017 Aug; 74(15):2851-2874. PubMed ID: 28534083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurotoxic or neuroprotective: Post-translational modifications of α-synuclein at the cross-roads of functions.
    Gadhavi J; Patel M; Bhatia D; Gupta S
    Biochimie; 2022 Jan; 192():38-50. PubMed ID: 34582997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inoculation of α-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve.
    Uemura N; Yagi H; Uemura MT; Hatanaka Y; Yamakado H; Takahashi R
    Mol Neurodegener; 2018 May; 13(1):21. PubMed ID: 29751824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progression of phosphorylated α-synuclein in Macaca fuscata.
    Kawakami I; Motoda A; Hashimoto M; Shimozawa A; Masuda-Suzukake M; Ohtani R; Takase M; Kumashiro M; Samejima K; Hasegawa M
    Brain Pathol; 2021 Sep; 31(5):e12952. PubMed ID: 33754430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Visualization of early oligomeric α-synuclein pathology and its impact on the dopaminergic system in the (Thy-1)-h[A30P]α-syn transgenic mouse model.
    Behere A; Thörnqvist PO; Winberg S; Ingelsson M; Bergström J; Ekmark-Lewén S
    J Neurosci Res; 2021 Oct; 99(10):2525-2539. PubMed ID: 34292621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Models of α-synuclein aggregation in Parkinson's disease.
    Giráldez-Pérez R; Antolín-Vallespín M; Muñoz M; Sánchez-Capelo A
    Acta Neuropathol Commun; 2014 Dec; 2():176. PubMed ID: 25497491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beyond α-synuclein transfer: pathology propagation in Parkinson's disease.
    Hansen C; Li JY
    Trends Mol Med; 2012 May; 18(5):248-55. PubMed ID: 22503115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.